Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0
|
作者：
Kurbacher, Christian M. [1 ]
Fischer, Lotta Ada [2 ]
Heinrich, Georg [3 ]
Herz, Susanne [1 ]
Schott, Alexander [1 ]
Kurbacher, A. Tabea [1 ]
Kurbacher, Jutta Anna [4 ]
Rudlowski, Christian [5 ]
Warm, Mathias R. [2 ]
机构：
[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany
[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany
[3] Praxis Gynakol Onkol, Furstenwalde, Germany
[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany
[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
552
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
    Abdel-Razeq, Hikmat
    Sharaf, Baha'
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 727 - 735
  • [22] The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
    Aranda-Gutierrez, Alejandro
    Meraz-Brenez, Andres
    Gonzalez-Sanchez, Hector Raul
    Verduzco-Aguirre, Haydee Cristina
    Martinez-Cannon, Bertha Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
    Hui, Rina
    de Boer, Richard
    Lim, Elgene
    Yeo, Belinda
    Lynch, Jodi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 14
  • [24] Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative breast cancer in Japan
    Futamura, Manabu
    Nakayama, Takahiro
    Yoshinami, Tersuhiro
    Oshiro, Chiya
    Ishihara, Mikiya
    Morita, Midori
    Watanabe, Akira
    Taniguchi, Azusa
    Tsukabe, Masami
    Shimoda, Masafumi
    Mitta, Kanae
    Chihara, Yoko
    Yasojima, Hiroyuki
    Ouchi, Yoshimi
    Tokumaru, Yoshihisa
    Ishihara, Takuma
    Masuda, Norikazu
    CANCER RESEARCH, 2023, 83 (05)
  • [25] CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
    Pantano, F.
    Scafetta, R.
    Curigliano, G.
    Criscitiello, C.
    Botticelli, A.
    Caputo, R.
    D'Auria, G.
    Garrone, O.
    Gori, S.
    Meattini, I.
    Minelli, M.
    Piras, M.
    Rossi, L.
    Stucci, L. S.
    Tagliaferri, B.
    Toss, A.
    Vernieri, C.
    Vici, P.
    Tonini, G.
    Santini, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S346 - S347
  • [26] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 469 - 477
  • [28] Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors
    Mo, Hanjie
    Renna, Catherine E.
    Moore, Halle C. F.
    Abraham, Jame
    Kruse, Megan L.
    Montero, Alberto J.
    LeGrand, Susan B.
    Wang, Lu
    Budd, G. Thomas
    CLINICAL BREAST CANCER, 2022, 22 (02) : 143 - 148
  • [29] CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S205 - S209
  • [30] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Carlo Messina
    Carlo Cattrini
    Giulia Buzzatti
    Luigi Cerbone
    Elisa Zanardi
    Marco Messina
    Francesco Boccardo
    Breast Cancer Research and Treatment, 2018, 172 : 9 - 21
12345